Gruppo Italiano Malattie EMatologiche dell'Adulto: Leukemia, Myeloid, Acute trials

The registry lists 20 Leukemia, Myeloid, Acute studies with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor. 6 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 7Phase 3 1No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory PracticeNot yet recruitingNCT07867704Not applicable
• Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTionsRecruitingNCT07080970
• Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid LeukemiaNot yet recruitingNCT06667973Phase 2
• Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)RecruitingNCT06513273
• Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid NeoplasmsRecruitingNCT04460950
• Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AMLRecruitingNCT04168502Phase 3
• Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00775593Phase 2Results posted
• Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid LeukemiaStatus unknownNCT04867928Phase 2
• Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxActive, not recruitingNCT04763928Phase 2
• Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96CompletedNCT04589728
• Role of Adrenomedullin in Leukemic Endosteal/Vascular NichesActive, not recruitingNCT04460963Not applicable
• Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid LeukemiaTerminatedNCT04342962Phase 2
• Long-term Outcomes for Acute Myeloid Leukemia PatientsStatus unknownNCT03755856
• Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid LeukemiaCompletedNCT03455504Phase 2
• Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)TerminatedNCT03410407
• Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid LeukemiaCompletedNCT02986620
• Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) PatientsTerminatedNCT01570465
• Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01452646Phase 2
• Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01154439Phase 1
• AML Treatment in Untreated Adult PatientsStatus unknownNCT00449319Not applicable